A detailed history of Pnc Financial Services Group, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 370 shares of MDGL stock, worth $117,323. This represents 0.0% of its overall portfolio holdings.

Number of Shares
370
Previous 375 1.33%
Holding current value
$117,323
Previous $105,000 25.71%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$212.22 - $292.96 $1,061 - $1,464
-5 Reduced 1.33%
370 $78,000
Q2 2024

Aug 09, 2024

BUY
$193.33 - $291.99 $7,539 - $11,387
39 Added 11.61%
375 $105,000
Q1 2024

May 10, 2024

BUY
$171.37 - $283.23 $41,300 - $68,258
241 Added 253.68%
336 $89,000
Q4 2023

Feb 09, 2024

BUY
$120.4 - $237.13 $2,408 - $4,742
20 Added 26.67%
95 $21,000
Q3 2023

Nov 13, 2023

BUY
$146.04 - $225.78 $3,066 - $4,741
21 Added 38.89%
75 $10,000
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $8,155 - $12,480
40 Added 285.71%
54 $12,000
Q1 2022

May 12, 2022

SELL
$55.89 - $101.89 $335 - $611
-6 Reduced 30.0%
14 $1,000
Q4 2021

Feb 11, 2022

BUY
$72.34 - $95.09 $72 - $95
1 Added 5.26%
20 $1,000
Q3 2021

Nov 05, 2021

SELL
$78.35 - $105.02 $78 - $105
-1 Reduced 5.0%
19 $1,000
Q2 2021

Aug 06, 2021

SELL
$97.2 - $137.59 $194 - $275
-2 Reduced 9.09%
20 $1,000
Q1 2021

May 07, 2021

BUY
$108.54 - $125.2 $217 - $250
2 Added 10.0%
22 $2,000
Q2 2020

Aug 07, 2020

BUY
$60.13 - $125.71 $360 - $754
6 Added 42.86%
20 $2,000
Q4 2018

Feb 08, 2019

SELL
$94.77 - $215.54 $128,602 - $292,487
-1,357 Reduced 98.98%
14 $1,000
Q3 2018

Nov 09, 2018

SELL
$207.3 - $300.31 $3,109 - $4,504
-15 Reduced 1.08%
1,371 $0
Q2 2018

Aug 10, 2018

SELL
$101.55 - $313.9 $52,704 - $162,914
-519 Reduced 27.24%
1,386 $0
Q1 2018

May 11, 2018

BUY
$93.35 - $149.04 $177,831 - $283,921
1,905 New
1,905 $0

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.42B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.